S&P 500   4,009.93 (+0.97%)
DOW   32,631.79 (+0.73%)
QQQ   310.25 (+1.02%)
AAPL   159.00 (+0.86%)
MSFT   277.80 (+0.93%)
META   202.70 (+1.01%)
GOOGL   102.47 (+1.43%)
AMZN   98.27 (+1.06%)
TSLA   192.33 (+1.66%)
NVDA   267.74 (+1.38%)
NIO   9.31 (+1.20%)
BABA   97.26 (-1.16%)
AMD   95.79 (+1.30%)
T   18.79 (+0.37%)
F   11.73 (+1.12%)
MU   61.00 (+2.90%)
CGC   1.83 (+1.11%)
GE   93.82 (+0.73%)
DIS   95.70 (+0.93%)
AMC   5.06 (-1.75%)
PFE   40.17 (+0.45%)
PYPL   73.32 (+0.85%)
NFLX   326.40 (+0.89%)
S&P 500   4,009.93 (+0.97%)
DOW   32,631.79 (+0.73%)
QQQ   310.25 (+1.02%)
AAPL   159.00 (+0.86%)
MSFT   277.80 (+0.93%)
META   202.70 (+1.01%)
GOOGL   102.47 (+1.43%)
AMZN   98.27 (+1.06%)
TSLA   192.33 (+1.66%)
NVDA   267.74 (+1.38%)
NIO   9.31 (+1.20%)
BABA   97.26 (-1.16%)
AMD   95.79 (+1.30%)
T   18.79 (+0.37%)
F   11.73 (+1.12%)
MU   61.00 (+2.90%)
CGC   1.83 (+1.11%)
GE   93.82 (+0.73%)
DIS   95.70 (+0.93%)
AMC   5.06 (-1.75%)
PFE   40.17 (+0.45%)
PYPL   73.32 (+0.85%)
NFLX   326.40 (+0.89%)
S&P 500   4,009.93 (+0.97%)
DOW   32,631.79 (+0.73%)
QQQ   310.25 (+1.02%)
AAPL   159.00 (+0.86%)
MSFT   277.80 (+0.93%)
META   202.70 (+1.01%)
GOOGL   102.47 (+1.43%)
AMZN   98.27 (+1.06%)
TSLA   192.33 (+1.66%)
NVDA   267.74 (+1.38%)
NIO   9.31 (+1.20%)
BABA   97.26 (-1.16%)
AMD   95.79 (+1.30%)
T   18.79 (+0.37%)
F   11.73 (+1.12%)
MU   61.00 (+2.90%)
CGC   1.83 (+1.11%)
GE   93.82 (+0.73%)
DIS   95.70 (+0.93%)
AMC   5.06 (-1.75%)
PFE   40.17 (+0.45%)
PYPL   73.32 (+0.85%)
NFLX   326.40 (+0.89%)
S&P 500   4,009.93 (+0.97%)
DOW   32,631.79 (+0.73%)
QQQ   310.25 (+1.02%)
AAPL   159.00 (+0.86%)
MSFT   277.80 (+0.93%)
META   202.70 (+1.01%)
GOOGL   102.47 (+1.43%)
AMZN   98.27 (+1.06%)
TSLA   192.33 (+1.66%)
NVDA   267.74 (+1.38%)
NIO   9.31 (+1.20%)
BABA   97.26 (-1.16%)
AMD   95.79 (+1.30%)
T   18.79 (+0.37%)
F   11.73 (+1.12%)
MU   61.00 (+2.90%)
CGC   1.83 (+1.11%)
GE   93.82 (+0.73%)
DIS   95.70 (+0.93%)
AMC   5.06 (-1.75%)
PFE   40.17 (+0.45%)
PYPL   73.32 (+0.85%)
NFLX   326.40 (+0.89%)
Most-Upgraded Stocks   Most-Downgraded Stocks  
NASDAQ:SGEN

Seagen - SGEN News Today

$203.02
+3.42 (+1.71%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$199.50
▼
$203.19
50-Day Range
$130.49
▼
$203.02
52-Week Range
$105.43
▼
$203.19
Volume
1.26 million shs
Average Volume
2.02 million shs
Market Capitalization
$37.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$188.33
Get Seagen News Delivered to You Automatically

Sign up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.


SGEN Media Mentions By Week

SGEN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SGEN
News Sentiment
▼
0.34

0.61
▲
Average
Medical
News Sentiment

SGEN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SGEN Articles
This Week
▼
12

6
▲
SGEN Articles
Average Week

SourceHeadline
marketbeat.com logoLion Street Advisors LLC Invests $238,000 in Seagen Inc. (NASDAQ:SGEN)
marketbeat.com - March 29 at 6:58 AM
marketbeat.com logoWestern Financial Corp CA Takes $604,000 Position in Seagen Inc. (NASDAQ:SGEN)
marketbeat.com - March 28 at 8:01 AM
marketbeat.com logoSeagen Inc. (NASDAQ:SGEN) Given Average Recommendation of "Hold" by Brokerages
marketbeat.com - March 27 at 6:31 AM
marketbeat.com logoAssenagon Asset Management S.A. Sells 72,100 Shares of Seagen Inc. (NASDAQ:SGEN)
marketbeat.com - March 27 at 4:46 AM
marketbeat.com logo3 Dividend Contenders to Buy Now for Long-Term Gains Later (SGEN)
marketbeat.com - March 22 at 7:00 AM
marketbeat.com logoPfizer’s Latest Acquisition Strengthens the Case for PFE Stock (SGEN)
marketbeat.com - March 15 at 12:00 PM
MarketBeat logoSeagen (NASDAQ:SGEN) Now Covered by Analysts at StockNews.com
americanbankingnews.com - March 25 at 5:34 AM
MarketBeat logoSeagen (NASDAQ:SGEN) Stock Rating Lowered by Berenberg Bank
americanbankingnews.com - March 24 at 7:56 AM
MarketBeat logoSeagen (NASDAQ:SGEN) PT Lowered to $129.00
americanbankingnews.com - March 23 at 2:52 AM
MarketBeat logoTruist Financial Increases Seagen (NASDAQ:SGEN) Price Target to $229.00
americanbankingnews.com - March 22 at 1:50 AM
MarketBeat logoSeagen (NASDAQ:SGEN) Coverage Initiated at StockNews.com
americanbankingnews.com - March 20 at 8:38 AM
MarketBeat logoSeagen Inc. (NASDAQ:SGEN) CMO Sells $1,998,100.00 in Stock
americanbankingnews.com - March 20 at 4:44 AM
finance.yahoo.com logoWhy Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?
finance.yahoo.com - March 17 at 1:33 PM
finance.yahoo.com logoSeagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
finance.yahoo.com - March 14 at 8:57 PM
benzinga.com logoShareholder Alert: Ademi LLP investigates whether Seagen Inc. has obtained a Fair Price in its transaction with Pfizer
benzinga.com - March 14 at 5:30 AM
msn.com logoSeagen Unusual Options Activity For March 13
msn.com - March 14 at 5:30 AM
markets.businessinsider.com logoBMO Capital downgrades Seagen (SGEN) to a Hold
markets.businessinsider.com - March 14 at 5:30 AM
barrons.com logoPfizer Rolls the Dice on Seagen in $43 Billion Deal. The Risks It Faces.
barrons.com - March 14 at 5:30 AM
markets.businessinsider.com logoJMP Securities downgrades Seagen (SGEN) to a Hold
markets.businessinsider.com - March 14 at 5:30 AM
businesswire.com logoSEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN
businesswire.com - March 13 at 8:21 PM
businesswire.com logoSGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to Shareholders
businesswire.com - March 13 at 9:33 AM
finance.yahoo.com logoPfizer Invests $43 Billion to Battle Cancer
finance.yahoo.com - March 13 at 7:39 AM
finance.yahoo.com logoThe five-year returns have been impressive for Seagen (NASDAQ:SGEN) shareholders despite underlying losses increasing
finance.yahoo.com - March 5 at 8:58 AM
finance.yahoo.com logoEstimating The Fair Value Of Seagen Inc. (NASDAQ:SGEN)
finance.yahoo.com - March 1 at 8:40 AM
finance.yahoo.com logoA Seagen Inc. (NASDAQ:SGEN) insider lowered their holding by 16% earlier this year
finance.yahoo.com - February 25 at 10:45 AM
finance.yahoo.com logoSeagen Full Year 2022 Earnings: Beats Expectations
finance.yahoo.com - February 17 at 10:41 AM
finance.yahoo.com logoWhy Seattle Genetics, Alkermes Are Currently Outperforming Their Peers
finance.yahoo.com - February 16 at 1:29 PM
finance.yahoo.com logoSeagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
finance.yahoo.com - February 13 at 8:43 PM
finance.yahoo.com logoSeagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
finance.yahoo.com - January 19 at 5:13 PM
finance.yahoo.com logoSeagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
finance.yahoo.com - January 19 at 12:12 PM
finance.yahoo.com logoSeagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - December 20 at 7:40 AM
finance.yahoo.com logoAstellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - December 20 at 7:40 AM
finance.yahoo.com logoSeagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma
finance.yahoo.com - December 12 at 4:47 PM
finance.yahoo.com logoSeagen Inc.'s (NASDAQ:SGEN) Intrinsic Value Is Potentially 98% Above Its Share Price
finance.yahoo.com - December 7 at 5:46 PM
finance.yahoo.com logoSeagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - December 1 at 10:08 AM
finance.yahoo.com logoInstitutional owners may consider drastic measures as Seagen Inc.'s (NASDAQ:SGEN) recent US$1.2b drop adds to long-term losses
finance.yahoo.com - November 17 at 8:47 AM
finance.yahoo.com logoSeagen Names David R. Epstein as Chief Executive Officer and Director
finance.yahoo.com - November 10 at 7:41 PM
finance.yahoo.com logoSeagen Appoints Sandra M. Swain, M.D., to Board of Directors
finance.yahoo.com - November 10 at 7:41 PM
finance.yahoo.com logoSeagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
finance.yahoo.com - November 10 at 7:41 PM
finance.yahoo.com logoSeagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
finance.yahoo.com - November 10 at 7:41 PM
markets.businessinsider.com logoAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Seagen (SGEN), Alnylam Pharma (ALNY) and BioMarin Pharmaceutical (BMRN)
markets.businessinsider.com - October 31 at 1:16 AM
nasdaq.com logoSeagen Inc Q3 Loss decreases, but misses estimates
nasdaq.com - October 27 at 11:05 PM
seekingalpha.com logoSeagen Inc. (SGEN) Q3 2022 Earnings Call Transcript
seekingalpha.com - October 27 at 11:05 PM
finance.yahoo.com logoSeagen Reports Third Quarter 2022 Financial Results
finance.yahoo.com - October 27 at 5:56 PM
msn.com logoA Bearish Sign Appears On Seagen's Chart
msn.com - October 25 at 5:05 PM
msn.com logoWhat 9 Analyst Ratings Have To Say About Seagen
msn.com - October 25 at 5:05 PM
finance.yahoo.com logoInvesting in Seagen (NASDAQ:SGEN) five years ago would have delivered you a 116% gain
finance.yahoo.com - October 19 at 5:38 PM
seekingalpha.com logoLAVA Therapeutics: Assessing A Promising Innovator (NASDAQ:LVTX) - Seeking Alpha
seekingalpha.com - October 18 at 8:12 AM
benzinga.com logoWhat 8 Analyst Ratings Have To Say About Seagen - Seagen (NASDAQ:SGEN) - Benzinga
benzinga.com - October 13 at 6:49 PM
benzinga.com logoMorgan Stanley Maintains Overweight Rating for Seagen: Here's What You Need To Know - Seagen (NASDAQ:SGEN - Benzinga
benzinga.com - October 13 at 1:49 PM
finance.yahoo.com logoNew Veeva Link Applications Give Clinical Teams Real-Time Intelligence to Optimize Site Selection and Trial Design - Yahoo Finance
finance.yahoo.com - October 13 at 7:54 AM
fool.com logoIs Seagen Stock a Buy Now? - The Motley Fool
fool.com - October 12 at 4:23 PM
nasdaq.com logoIs Seagen Stock a Buy Now? - Nasdaq
nasdaq.com - October 12 at 11:23 AM
benzinga.com logoBMO Capital Upgrades Seagen: Here's What You Need To Know - Seagen (NASDAQ:SGEN) - Benzinga
benzinga.com - October 11 at 2:12 PM
businesswire.com logoSeagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022 - Business Wire
businesswire.com - October 7 at 6:53 PM
nasdaq.com logoHere's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation
nasdaq.com - October 7 at 8:06 AM
Get Seagen News Delivered to You Automatically

Sign up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:SGEN) was last updated on 3/29/2023 by MarketBeat.com Staff